ZA9410089B - Methods of inhibiting imperfect tissue repair - Google Patents

Methods of inhibiting imperfect tissue repair

Info

Publication number
ZA9410089B
ZA9410089B ZA9410089A ZA9410089A ZA9410089B ZA 9410089 B ZA9410089 B ZA 9410089B ZA 9410089 A ZA9410089 A ZA 9410089A ZA 9410089 A ZA9410089 A ZA 9410089A ZA 9410089 B ZA9410089 B ZA 9410089B
Authority
ZA
South Africa
Prior art keywords
methods
tissue repair
inhibiting
imperfect tissue
inhibiting imperfect
Prior art date
Application number
ZA9410089A
Other languages
English (en)
Inventor
Thomas Frank Bumol
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA9410089B publication Critical patent/ZA9410089B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9410089A 1993-12-21 1994-12-19 Methods of inhibiting imperfect tissue repair ZA9410089B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,150 US5574047A (en) 1993-12-21 1993-12-21 Methods of inhibiting imperfect tissue repair

Publications (1)

Publication Number Publication Date
ZA9410089B true ZA9410089B (en) 1996-06-19

Family

ID=22622741

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9410089A ZA9410089B (en) 1993-12-21 1994-12-19 Methods of inhibiting imperfect tissue repair

Country Status (17)

Country Link
US (2) US5574047A (ko)
EP (1) EP0664122A1 (ko)
JP (1) JPH07215862A (ko)
KR (1) KR950016740A (ko)
CN (1) CN1051921C (ko)
AU (1) AU690596B2 (ko)
CA (1) CA2138454A1 (ko)
CZ (1) CZ287766B6 (ko)
HU (1) HUT71343A (ko)
IL (1) IL112043A (ko)
NO (1) NO313487B1 (ko)
NZ (1) NZ270180A (ko)
PH (1) PH31324A (ko)
RU (1) RU2133121C1 (ko)
TW (1) TW321600B (ko)
UA (1) UA37212C2 (ko)
ZA (1) ZA9410089B (ko)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
AU708374B2 (en) * 1995-02-06 1999-08-05 Eli Lilly And Company Methods of inhibiting effects of IL-6
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
IL125523A0 (en) * 1996-01-29 1999-03-12 Lilly Co Eli Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
US5670523A (en) * 1996-01-29 1997-09-23 Eli Lilly And Company Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
ID15917A (id) * 1996-01-29 1997-08-21 Lilly Co Eli Metode untuk menghambat tumor usus besar
US6063575A (en) * 1997-03-21 2000-05-16 University Of Maryland, At Baltimore Assay for measuring the activity and fidelity of DNA replication and kit therefor
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
JP2001518453A (ja) * 1997-09-29 2001-10-16 ユニバーシティ オブ メリーランド， ボルチモア 悪性腫瘍の生体マーカーとしての改変されたｄｎａシンセソーム成分
WO1999016469A1 (en) * 1997-09-29 1999-04-08 University Of Maryland, Baltimore Altered dna synthesome components as biomarkers for malignancy
US6093543A (en) * 1998-04-11 2000-07-25 University Of Maryland, Baltimore Method for detecting the presence of malignant cells using a multi-protein DNA replication complex
HUP0200871A3 (en) 1999-05-04 2004-04-28 Strakan Int Ltd Androgen glycosides and androgenic activity thereof
WO2002060972A2 (en) * 2001-01-29 2002-08-08 Ndsu Research Foundation Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
JP4212036B2 (ja) * 2003-06-19 2009-01-21 ローム株式会社 定電圧発生器

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
EP0651637B1 (en) * 1992-07-20 2006-10-04 Massachusetts Institute Of Technology Control of wound scar production with calmodulin inhibitors or protein kinase c inhibitors

Also Published As

Publication number Publication date
NO944922D0 (no) 1994-12-19
HU9403674D0 (en) 1995-02-28
NO313487B1 (no) 2002-10-14
RU94044490A (ru) 1996-10-20
US5686467A (en) 1997-11-11
AU8155794A (en) 1995-06-29
CA2138454A1 (en) 1995-06-22
CZ322394A3 (en) 1995-09-13
UA37212C2 (uk) 2001-05-15
CZ287766B6 (en) 2001-01-17
CN1051921C (zh) 2000-05-03
AU690596B2 (en) 1998-04-30
TW321600B (ko) 1997-12-01
RU2133121C1 (ru) 1999-07-20
NZ270180A (en) 1997-07-27
IL112043A0 (en) 1995-03-15
PH31324A (en) 1998-07-06
US5574047A (en) 1996-11-12
CN1109330A (zh) 1995-10-04
JPH07215862A (ja) 1995-08-15
KR950016740A (ko) 1995-07-20
HUT71343A (en) 1995-11-28
EP0664122A1 (en) 1995-07-26
IL112043A (en) 2000-02-29
NO944922L (no) 1995-06-22

Similar Documents

Publication Publication Date Title
HU9403674D0 (en) Methods of inhibiting imperfect tissue repair
AU7219894A (en) Surgical repair kit and method of use
IL111224A0 (en) Methods for inhibiting bone loss
IL140368A0 (en) Method of tissue repair ii
AU1176595A (en) Methods of repairing connective tissues
PL313740A1 (en) Method of
AU4584893A (en) Magnetotherapy apparatus
EP0782444A4 (en) METHOD FOR INHIBITING BRADYKININ-ASSOCIATED DISORDERS
ZA957949B (en) Methods of inhibiting endometrial mitroses
AU1378495A (en) Methods and compositions for inhibiting thrombogenesis
PL310620A1 (en) Method of obtaining condenset carbapenemic derivatives
PL303946A1 (en) Method of obtaining indoles
AU5611398A (en) Method of treating or inhibiting neutropenia
PL297500A1 (en) Method of obtaining 4-phenyl-benzophenone
GB9319848D0 (en) Tissue repair
AU3984195A (en) Procedure for anticorrosive treatment
GB9518464D0 (en) Tissue repair
GB9307004D0 (en) Method of treatment
GB9321971D0 (en) Method of treatment
GB9321796D0 (en) Method of treatment
PL299255A1 (en) Method of obtaining meproscilarine
ZA944893B (en) Kit and method for targeting
GB9418240D0 (en) Tissue repair
GB9417996D0 (en) Tissue repair
GB9325838D0 (en) Method of testing